An online course on Disease Modeling and Target Discovery launched 7 months ago by clinical stage generative artificial intelligence (AI)-driven biotechnology company Insilico Medicine has surpassed 2,500 users. The free course provides a broad overview of the latest advances in AI drug discovery with seven lectures covering topics such as target selection criteria, the use of computational approaches, and emerging trends.
Credit: Insilico Medicine
An online course on Disease Modeling and Target Discovery launched 7 months ago by clinical stage generative artificial intelligence (AI)-driven biotechnology company Insilico Medicine has surpassed 2,500 users. The free course provides a broad overview of the latest advances in AI drug discovery with seven lectures covering topics such as target selection criteria, the use of computational approaches, and emerging trends.
Led by experts in machine learning and disease modeling at Insilico Medicine, the course uses case studies to illustrate concepts, and provides users with an opportunity to explore a demo version of PandaOmics, Insilico Medicine’s generative AI tool for target discovery, a key part of the Company’s end-to-end Pharma.AI platform. This AI platform is used by over 40 pharmaceutical companies and has driven the development of 30+ internal novel therapeutic pipeline assets – including a lead drug for for idiopathic pulmonary fibrosis in Phase II clinical trials and four other drugs for cancer, COVID-19, and IBD in Phase I trials.
“We are very encouraged by the popularity of this course and the growing interest in AI drug discovery,” says Insilico Medicine founder and CEO Alex Zhavoronkov, PhD, who is one of the course instructors. “We are committed to accelerating the discovery and development of new therapeutics by making technological breakthroughs accessible to all scientists, including students, who might be interested in pursuing AI drug discovery,”
The course provides participants with: .
- in-depth knowledge of the challenges and opportunities in drug target discovery, and the emerging role of AI;
- practical skills in identifying and evaluating potential drug targets;
- knowledge of the latest trends and emerging topics in target discovery, such as the use of large language models and the evolution of the druggable genome concept;
- exposure to several case studies that illustrate the practical application of the concepts covered.
The course is designed to be accessible to anyone interested in drug discovery, biomedical research, and healthcare innovation, including researchers, scientists, pharmaceutical professionals and students pursuing a degree in molecular biology, chemistry, or related fields.
About Insilico Medicine
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine delivers breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS), and aging-related diseases. www.insilico.com
